An observational study in Breast Carcinoma, sponsored by University of Southern California. Recruiting at 2 sites in United States. Open to female participants aged 30 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by University of Southern California · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Breast Neoplasms by University of Southern California — 6 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · University of Southern California.
Among the 39 studies in Breast Neoplasms by University of Southern California, this one is the only one that started in 2025, is one of 9 observational ones, and was the 39th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →6 of the 39 studies in Breast Neoplasms by University of Southern California are open now, in 1 country. Recruiting first, the newest first:
University of Southern California · Sites in United States
Ages 18+ · Women only
University of Southern California · Sites in United States
Ages 18+ · Healthy volunteers
University of Southern California · Sites in United States
Ages 18+ · Women only
University of Southern California · Sites in United States
Ages 18+ · Women only
University of Southern California · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 30 Years to 75 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 26 across the 30 interventional studies, 135 across the 9 observational. Of the 25 that completed or were terminated, 4 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Southern California is the lead sponsor of 793 studies on the registry; 138 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 32 (45%) have results posted.
5 of the studies in Breast Neoplasms by University of Southern California that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01802346University of Southern CaliforniaControlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer | 2026-12-31 |
| NCT04616248University of Southern CaliforniaIn Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | 2027-01-09 |
| NCT05786664University of Southern CaliforniaBreast Cancer Survivorship Biorepository | 2027-04-11 |
| NCT07076147University of Southern CaliforniaBreast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer | 2027-06-02 |
| NCT06422455University of Southern CaliforniaAccess to Genetic Testing in Underserved Patients With Cancer | 2027-10-24 |
Add all 5 to your calendar (.ics) → With an account.
Among the 39 studies in Breast Neoplasms by University of Southern California, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study assesses breast cancer screening adherence for women at moderately increased risk for developing breast cancer based on gene mutation status or empiric risk model estimates. It also seeks to determine facilitators and barriers to screening.
PRIMARY OBJECTIVE:
I. Among women without a history of breast cancer: to compare women with moderate risk breast cancer gene mutations (Mutation Carrier Group) to women with a 20-40% empiric lifetime risk of breast cancer (Empiric Risk Group) in terms of how likely they are to undergo recommended breast MRI screening.
OUTLINE: This is an observational study.
Patients complete a questionnaire and have their medical records reviewed on study.
Women provided with a breast cancer risk assessment by genetic counselors at USC Norris or LA General Hospital with either genetic test results showing moderately increased breast cancer risk due to a pathogenic/likely pathogenic variant in ATM, CHEK2, BARD1, RAD51C, or RAD51D or a calculated lifetime breast cancer risk estimates between 20% and 40% according to the Tyrer-Cuzick V8.0B empiric risk model who are recommended to undergo annual breast MRI and/or annual mammogram.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* >= 30 years
Women with either:
Exclusion Criteria:
* History of breast cancer before genetic counseling at University of Southern California (USC)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients complete a questionnaire and have their medical records reviewed on study.
Other: Non-Interventional Study
Non-interventional study
Proportion of women who undergo a screening breast MRI within 12 months of genetic test counseling
Will be calculated for each of the 4 Hospital-by-Age subgroups for the 2 risk groups; then a one-sided, α=0.05 Mantel Haenszel test, stratifying by hospital and age, will be used to compare the Mutation Carrier Risk and the Empiric Risk groups in terms of adherence to screening MRI. Homogeneity of odds ratios will be tested to ensure that difference (odds ratio) between the two risk groups is fairly consistent across the 4 strata.
Time frame: Up to 2 years
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Southern California →